CJC-1295 + Ipamorelin
A synergistic GHRH/GHRP combination studied for producing robust, pulsatile growth hormone release with favourable selectivity profiles.
CJC-1295 is a 30-amino-acid synthetic analogue of growth-hormone-releasing hormone (GHRH) that has been modified with a Drug Affinity Complex (DAC) technology — specifically a maleimidoproprionic acid group that reacts covalently with albumin lysine residues, extending its plasma half-life from minutes to approximately 6–8 days. This makes it an excellent tool for sustained GHRH receptor stimulation studies without the need for frequent administration.
Ipamorelin is a pentapeptide ghrelin mimetic and growth-hormone secretagogue receptor (GHSR) agonist noted for its high selectivity: unlike older GHRPs such as GHRP-6 or GHRP-2, it shows minimal stimulation of cortisol, prolactin, or ACTH release at research doses, making it a cleaner pharmacological probe for GHSR biology. Its pulsatile mechanism of GH release — mimicking natural ultradian rhythms — has made it a popular comparator in growth hormone axis research.
When combined, CJC-1295 and Ipamorelin act on complementary receptor systems (GHRH-R and GHSR-1a) and produce synergistic GH pulses via different second-messenger pathways (cAMP and IP3/DAG, respectively). This combination is extensively used in research models investigating GH axis regulation, IGF-1 signalling, body composition changes, and the physiology of growth hormone secretion.
For research purposes only. Not for human consumption.